‌

US Patent 10493072 Lanthionine synthetase C-like 2-based therapeutics

Patent 10493072 was granted and assigned to Landos Biopharma on December, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Landos Biopharma

0

Current Assignee

Landos Biopharma

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Raquel Hontecillas0

Richard Gandour0

Adria Carbo Barrios0

Josep Bassaganya-Riera0

Julian D. Cooper0

Date of Patent

December 3, 2019

0

Patent Application Number

162279400

Date Filed

December 20, 2018

0

Patent Citations Received

US Patent 11492342 Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridin-2yl)methanone)

US Patent 10682349 Lanthionine synthetase C-like 2-based therapeutics

US Patent 10849895 Lanthionine synthetase C-like 2-based therapeutics

US Patent 11571419 Lanthionine synthetase C-like 2-based therapeutics

US Patent 11377437 Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same

Patent Primary Examiner

Emily A Bernhardt

0

Patent abstract

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10493072 Lanthionine synthetase C-like 2-based therapeutics

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.